Atezolizumab Trial for NSCLC Completes Primary Phase 3 Study

The Phase 3 study (NCT06267001) investigating atezolizumab in combination with tiragolumab for non-small cell lung cancer (NSCLC) has reached its primary completion as of 2025-12-16. This trial evaluated the efficacy and safety of the combination compared to placebo plus atezolizumab in participants who had undergone complete resection and adjuvant platinum-based chemotherapy.

Background

The study focused on non-small cell lung cancer (NSCLC), a common and serious form of lung cancer. The trial, officially titled "A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy," aimed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants who had undergone complete resection and adjuvant chemotherapy.

Trial design

The Phase 3 study, identified as NCT06267001, was designed to assess the combination of tiragolumab plus atezolizumab. It enrolled 56 participants diagnosed with non-small cell lung cancer (NSCLC) who had undergone complete resection and received adjuvant platinum-based chemotherapy. Participants were randomized to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab. The trial's purpose was to evaluate the efficacy and safety of these treatment regimens.

What this means

The primary completion of this Phase 3 study signifies that all participants have finished the main observation period as defined by the trial protocol. This milestone indicates that the collection of primary outcome data is complete, and the sponsor can now proceed with data analysis. The results of this study will be crucial in determining the potential role of tiragolumab plus atezolizumab as an adjuvant treatment option for patients with resected non-small cell lung cancer (NSCLC) who have received prior chemotherapy.

Source

This information was sourced from ClinicalTrials.gov, a public database of clinical studies. The primary completion status for study NCT06267001, titled "A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy," was updated on 2025-12-16 on clinicaltrials.gov.